ED
EDXC.US Endexx Corp
- Market cap
- USD 57.2K
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Mar 2025.
Is EDXC.US undervalued?
Graham numberThe Graham number of Endexx Corp cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Endexx Corp fundamental analysis
No fundamental analysis for Endexx Corp yet.
Endexx Corp stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Endexx Corp
Endexx Corporation develops and sells hemp-derived products for the health and wellness market under the CBD Unlimited brand in the United States and internationally. The company offers cannabidiol oils, topicals, capsules, snacks, and beverages, as well as equine products for dogs and cats under the PhytoBites brand. It serves medical, biotech, and life science industries. The company was formerly known as CBD Unlimited, Inc. and changed its name to Endexx Corporation in Ma…
Full company profileEndexx Corp financial statements
2025 annualized: Fiscal year 2025 is not finished. Income statement and cash flow are annualized from 2 quarters up to Mar 31, 2025, the balance sheet is the latest quarter. Figures change when the annual report is published.
Endexx Corp annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 126K | 221K | 418K | 798K | 1.50M | 1.97M | 651K | 2.14M | 3.91M | 1.66M | - |
| Gross Profit | 10.5K | 54.2K | 206K | 348K | 674K | 1.36M | -344K | 503K | -1.15M | 731K | - |
| Operating Income | -966K | -773K | -307K | -867K | -2.67M | -2.62M | -5.37M | -3.67M | -5.24M | -583K | -290K |
| EBITDA | -896K | -770K | -276K | -1.34M | -6.77M | -5.73M | -4.55M | -3.65M | -4.67M | -613K | -21.5M |
| Net Income | -1.17M | -777K | -669K | -1.74M | -11.4M | -8.06M | -6.81M | -4.90M | -6.50M | -3.40M | -23.8M |
| EPS | -0.01 | 0.00 | 0.00 | -0.01 | -0.03 | -0.02 | -0.01 | -0.01 | -0.01 | -0.01 | -0.04 |
| Balance Sheet | |||||||||||
| Total Assets | 1.64M | 218K | 441K | 757K | 3.60M | 2.99M | 1.76M | 13.3M | 10.3M | 11.4M | 1.54M |
| Total Liabilities | 1.86M | 2.57M | 2.71M | 3.13M | 8.36M | 13.5M | 11.7M | 23.0M | 30.1M | 32.5M | 34.1M |
| Shareholders' Equity | -216K | -2.35M | -2.27M | -2.37M | -4.76M | -10.6M | -9.99M | -9.43M | -17.6M | -19.1M | -30.6M |
| Cash & Short-term Investments | 23.4K | 86.5K | 22.9K | 208K | 62.3K | 4.65K | 20.9K | 657K | 7.64K | 7.51K | - |
| Total Debt | 82.4K | 127K | 1.55M | 1.58M | 2.77M | 4.90M | 6.90M | 10.0M | 15.4M | 15.0M | 14.9M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -223K | -135K | -383K | -587K | -3.17M | -2.50M | -3.72M | -1.46M | -1.62M | -452K | 222K |
| Capital Expenditure | 2.51K | 0.00 | 0.00 | 2.50K | 62.6K | 100K | 3.00 | 4.00 | 3.00 | 1.00 | 8.00 |
| Free Cash Flow | -226K | -135K | -383K | -590K | -3.23M | -2.60M | -3.72M | -1.46M | -1.62M | -452K | 222K |
| Ratios | |||||||||||
| ROA | -71.3% | -355.5% | -151.7% | -229.7% | -316.6% | -269.6% | -386.8% | -36.9% | -62.9% | -29.8% | -1,550.5% |
| Net Profit Margin | -926.2% | -351.8% | -159.8% | -217.9% | -760.3% | -409.0% | -1,046.6% | -229.0% | -166.3% | -205.2% | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Endexx Corp dividends
Endexx Corp has not paid dividends in the last 9 fiscal years.
Last stock split: 1:10 on Mar 8, 2002.
Who owns Endexx Corp
- Insiders 0.00%
- Institutions 0.00%
- Public & others 100.00%
- Shares outstanding 572M
- Free float 479M
Endexx Corp company profile
- Company name
- Endexx Corp
- Ticker
- EDXC.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Fiscal year end
- September
- Address
- 38246 North Hazelwood Circle, Cave Creek, AZ, United States, 85331
- Phone
- 480 595 6900
- Website
- endexx.com
About Endexx Corp
Endexx Corporation develops and sells hemp-derived products for the health and wellness market under the CBD Unlimited brand in the United States and internationally. The company offers cannabidiol oils, topicals, capsules, snacks, and beverages, as well as equine products for dogs and cats under the PhytoBites brand. It serves medical, biotech, and life science industries. The company was formerly known as CBD Unlimited, Inc. and changed its name to Endexx Corporation in May 2020. The company is based in Cave Creek, Arizona.
Endexx Corp management
3- Mr. Todd A. DavisDirector & CEO of CBD Unlimited Inc. · born 1966
- Brad ListermannInterim Chief Executive Officer
- Mr. Doug Williams CPAChief Financial Officer